» The experience and reputation of our principals and staff, particularly for their innovation and entrepreneurial drive, is the key force behind PulmoBioTech, where ideas become reality.

» Combining business experience and the highest academic and medical credentials, our staff are proven performers in small and large firms and have worked with a broad range of investment institutions.

» Our latest investment has been made through a recently formed Canadian Company, PulmoScience.

» PulmoScience is developing a range of new diagnostic procedures for the imaging of the circulatory system of the lungs. These products have the brand name PulmoBind.

» PulmoBind will almost totally eliminate any physical damage to patients during a lung scan (current scans involving nuclear medicine based diagnosis of Pulmonary Embolism are known to cause tissue damage), while at the same time giving the medical community sharper images and enhanced information, ultimately enabling better diagnostic judgments.

» PulmoScience is partly owned by the prestigious Montreal Heart Institute (www.icm-mhi.org) which funded the early stage work for this exciting new diagnostic technique. Dr Jocelyn Dupuis, the originator of this new technology, also has a stake in the Company.

» By bringing together the experience, imagination and drive of the inventor, the experience and facilities of the Montreal Heart Institute, and the managerial and financial capabilities of PulmoBioTech, a product has been created to capture a dominant position within its’ marketplace.